{
  "PMC11430164": {
    "pmid": "39346054",
    "title": "The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population",
    "study_parameters": [
       {
        "Study Parameters ID": 1452626581,
        "Variant Annotation ID": 1452626580,
        "Study Type": null,
        "Study Cases": 22,
        "Study Controls": 1,
        "Characteristics": "ticagrelor; variant alleles show altered CLint vs CYP3A4*1 (1.5–264% activity)",
        "Characteristics Type": "In vitro",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.05",
        "Ratio Stat Type": "CLint ratio",
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Han Chinese population",
        "Variant Annotation ID_norm": "1452626581"
      },
      {
        "Study Parameters ID": 1452626582,
        "Variant Annotation ID": 1452626560,
        "Study Type": null,
        "Study Cases": 22,
        "Study Controls": 1,
        "Characteristics": "ticagrelor; variant alleles show altered CLint vs CYP3A4*1 (1.5–264% activity)",
        "Characteristics Type": "In vitro",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.05",
        "Ratio Stat Type": "CLint ratio",
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Han Chinese population",
        "Variant Annotation ID_norm": "1452626582"
      },
      {
        "Study Parameters ID": 1452626583,
        "Variant Annotation ID": 1452626540,
        "Study Type": null,
        "Study Cases": 22,
        "Study Controls": 1,
        "Characteristics": "ticagrelor; variant alleles show altered CLint vs CYP3A4*1 (1.5–264% activity)",
        "Characteristics Type": "In vitro",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.05",
        "Ratio Stat Type": "CLint ratio",
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Han Chinese population",
        "Variant Annotation ID_norm": "1452626582"
      }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [],
    "var_fa_ann": [
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*2",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *2 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*2",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*3",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *3 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*3",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*4",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *4 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*4",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*5",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *5 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*5",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*9",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *9 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*9",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*14",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *14 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*14",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*15",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *15 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*15",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*16",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *16 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*16",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*17",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *17 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*17",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*19",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *19 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*19",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*24",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *24 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*24",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*28",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *28 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*28",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*29",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *29 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*29",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*31",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*31",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626580"
      },
      {
        "Variant Annotation ID": 1452626560,
        "Variant/Haplotypes": "CYP3A4*11",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *11 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*11",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626560"
      },
      {
        "Variant Annotation ID": 1452626560,
        "Variant/Haplotypes": "CYP3A4*18",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *18 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*18",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626560"
      },
      {
        "Variant Annotation ID": 1452626560,
        "Variant/Haplotypes": "CYP3A4*33",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*33",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626560"
      },
      {
        "Variant Annotation ID": 1452626540,
        "Variant/Haplotypes": "CYP3A4*10",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *10 is not associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*10",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": null,
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626560"
      },
      {
        "Variant Annotation ID": 1452626540,
        "Variant/Haplotypes": "CYP3A4*23",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *23 is not associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*23",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": null,
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626560"
      },
      {
        "Variant Annotation ID": 1452626540,
        "Variant/Haplotypes": "CYP3A4*32",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *32 is not associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*32",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": null,
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626560"
      },
      {
        "Variant Annotation ID": 1452626540,
        "Variant/Haplotypes": "CYP3A4*34",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *34 is not associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*34",
        "Specialty Population": null,
        "Assay type": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": null,
        "Functional terms": "clearance of",
        "Gene/gene product": null,
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
        "Comparison Metabolizer types": null,
        "PMID_norm": "39346054",
        "Variant Annotation ID_norm": "1452626560"
      }
    ]
  },
  "PMC10786722": {
    "pmid": "38216550",
    "title": "Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity",
    "study_parameters": [
      {
        "Study Parameters ID": 1452352264,
        "Variant Annotation ID": 1452352260,
        "Study Type": null,
        "Study Cases": 98.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.05",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352260"
      },
      {
        "Study Parameters ID": 1452352360,
        "Variant Annotation ID": 1452352325,
        "Study Type": null,
        "Study Cases": 298.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.01",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352325"
      },
      {
        "Study Parameters ID": 1452352324,
        "Variant Annotation ID": 1452352320,
        "Study Type": null,
        "Study Cases": 508.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.01",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352320"
      },
      {
        "Study Parameters ID": 1452352265,
        "Variant Annotation ID": 1452352415,
        "Study Type": "Cohort",
        "Study Cases": 11.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.001",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352415"
      },
      {
        "Study Parameters ID": 1452352266,
        "Variant Annotation ID": 1452352410,
        "Study Type": "Cohort",
        "Study Cases": 12.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.001",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352410"
      },
      {
        "Study Parameters ID": 1452352267,
        "Variant Annotation ID": 1452352420,
        "Study Type": "Cohort",
        "Study Cases": 22.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.0001",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352420"
      },
      {
        "Study Parameters ID": 1452352268,
        "Variant Annotation ID": 1452352440,
        "Study Type": "Cohort",
        "Study Cases": 98.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "< 0.05",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352440"
      },
      {
        "Study Parameters ID": 1452352269,
        "Variant Annotation ID": 1452352445,
        "Study Type": "Cohort",
        "Study Cases": 138.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "ns",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352445"
      },
      {
        "Study Parameters ID": 1452352270,
        "Variant Annotation ID": 1452352450,
        "Study Type": "Cohort",
        "Study Cases": 1077.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "ns",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352450"
      },
      {
        "Study Parameters ID": 1452352271,
        "Variant Annotation ID": 1452352455,
        "Study Type": "Cohort",
        "Study Cases": 212.0,
        "Study Controls": null,
        "Characteristics": "plasma dihydrouracil/uracil",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "ns",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1452352455"
      }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [],
    "var_fa_ann": [
      {
        "Variant Annotation ID": 1452352260,
        "Variant/Haplotypes": "rs56038477",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).\" NOTE: the HapB has two variants, and c.1129-5923C>G rs75017182 is the causative variant, a recent study has shown they are not in perfect LD in all populations [PMID: 38129972].",
        "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CC",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352260"
      },
      {
        "Variant Annotation ID": 1452352325,
        "Variant/Haplotypes": "rs1801160",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"The association between common DPYD genetic variants (MAF\u2009\u2265\u20091%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
        "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CC",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352325"
      },
      {
        "Variant Annotation ID": 1452352320,
        "Variant/Haplotypes": "rs2297595",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"The association between common DPYD genetic variants (MAF\u2009\u2265\u20091%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
        "Sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.",
        "Alleles": "CC + CT",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "TT",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352320"
      },
      {
        "Variant Annotation ID": 1452352415,
        "Variant/Haplotypes": "rs55886062",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"c.1679T>G (DPYD*13; rs55886062) encodes p.Ile560Ser; carriers showed significantly lower DPD activity than wild type (n=11, p<0.001; Fig.1).\"",
        "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CC",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352415"
      },
      {
        "Variant Annotation ID": 1452352410,
        "Variant/Haplotypes": "rs3918290",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"c.1905+1G>A (DPYD*2A; rs3918290) is a splice-site loss-of-function variant; carriers had markedly reduced DPD activity (n=12, p<0.001; Fig.1).\"",
        "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CC",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352410"
      },
      {
        "Variant Annotation ID": 1452352410,
        "Variant/Haplotypes": "rs67376798",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"c.2846A>T (rs67376798; p.Asp949Val) is a reduced-function variant; carriers showed significantly decreased DPD activity versus wild type (n=22, p<0.0001; Fig.1).\"",
        "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CC",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352410"
      },
      {
        "Variant Annotation ID": 1452352440,
        "Variant/Haplotypes": "rs1801265",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"c.85C>T (rs1801265; p.Cys29Arg) was analyzed among common DPYD variants (MAF≥1%) but showed no significant association with DPD activity (Fig.2).\"",
        "Sentence": "Genotypes CT + TT is not associated with activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": null,
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CC",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352440"
      },
      {
        "Variant Annotation ID": 1452352445,
        "Variant/Haplotypes": "rs1801158",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"c.1601G>A (rs1801158; p.Ser534Asn) was evaluated among common DPYD variants but was not significantly associated with DPD activity (Fig.2).\"",
        "Sentence": "Genotypes CT + TT is not associated with activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": null,
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "CC",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352445"
      },
      {
        "Variant Annotation ID": 1452352450,
        "Variant/Haplotypes": "rs1801159",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"c.1627A>G (rs1801159; p.Ile543Val) showed no significant difference in DPD activity among genotypes (Fig.2).\"",
        "Sentence": "Genotypes TC + CC is not associated with activity of DPYD as compared to genotype TT.",
        "Alleles": "TC + CC",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": null,
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "TT",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352450"
      },
      {
        "Variant Annotation ID": 1452352455,
        "Variant/Haplotypes": "rs17376848",
        "Gene": "DPYD",
        "Drug(s)": null,
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"c.1896T>C (rs17376848; p.Val632Ala) was included among common DPYD variants but was not significantly associated with DPD activity (Fig.2).\"",
        "Sentence": "Genotypes TC + CC is not associated with activity of DPYD as compared to genotype TT.",
        "Alleles": "TC + CC",
        "Specialty Population": null,
        "Assay type": "plasma dihydrouracil/uracil",
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": null,
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "When treated with/exposed to/when assayed with": null,
        "Multiple drugs And/or": null,
        "Cell type": null,
        "Comparison Allele(s) or Genotype(s)": "TT",
        "Comparison Metabolizer types": null,
        "PMID_norm": "38216550",
        "Variant Annotation ID_norm": "1452352455"
      }
    ]
  },
  "PMC10993165": {
    "pmid": "38568509",
    "title": "Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole\u2013Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis",
    "study_parameters": [
      {
        "Study Parameters ID": 1452437520,
        "Variant Annotation ID": 1452437420,
        "Study Type": "meta-analysis",
        "Study Cases": null,
        "Study Controls": null,
        "Characteristics": "2 studies, SJS/TEN v tolerant controls",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.001",
        "Ratio Stat Type": "OR",
        "Ratio Stat": 3.01,
        "Confidence Interval Start": 1.56,
        "Confidence Interval Stop": 5.8,
        "Biogeographical Groups": "Multiple groups",
        "Variant Annotation ID_norm": "1452437420"
      },
      {
        "Study Parameters ID": 1452437426,
        "Variant Annotation ID": 1452437420,
        "Study Type": "meta-analysis",
        "Study Cases": 158.0,
        "Study Controls": 226.0,
        "Characteristics": "2 studies, SCAR v tolerant controls",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.01",
        "Ratio Stat Type": "OR",
        "Ratio Stat": 2.23,
        "Confidence Interval Start": 1.2,
        "Confidence Interval Stop": 4.14,
        "Biogeographical Groups": "Multiple groups",
        "Variant Annotation ID_norm": "1452437420"
      },
      {
        "Study Parameters ID": 1452438988,
        "Variant Annotation ID": 1452438980,
        "Study Type": "meta-analysis",
        "Study Cases": 158.0,
        "Study Controls": 226.0,
        "Characteristics": "2 studies, SCAR v tolerant controls",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.01",
        "Ratio Stat Type": "OR",
        "Ratio Stat": 5.96,
        "Confidence Interval Start": 1.58,
        "Confidence Interval Stop": 22.56,
        "Biogeographical Groups": "Multiple groups",
        "Variant Annotation ID_norm": "1452438980"
      },
      {
        "Study Parameters ID": 1452438989,
        "Variant Annotation ID": 1452439000,
        "Study Type": "meta-analysis",
        "Study Cases": 158.0,
        "Study Controls": 226.0,
        "Characteristics": "2 studies, SCAR v tolerant controls",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.01",
        "Ratio Stat Type": "OR",
        "Ratio Stat": 3.47,
        "Confidence Interval Start": 1.42,
        "Confidence Interval Stop": 8.48,
        "Biogeographical Groups": "Multiple groups",
        "Variant Annotation ID_norm": "1452439000"
      },
      {
        "Study Parameters ID": 1452438990,
        "Variant Annotation ID": 1452439000,
        "Study Type": "meta-analysis",
        "Study Cases": null,
        "Study Controls": null,
        "Characteristics": "2 studies, SJS/TEN v tolerant controls",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": null,
        "Ratio Stat Type": "OR",
        "Ratio Stat": 5.13,
        "Confidence Interval Start": 1.96,
        "Confidence Interval Stop": 13.47,
        "Biogeographical Groups": "Multiple groups",
        "Variant Annotation ID_norm": "1452439000"
      }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1452437420,
        "Variant/Haplotypes": "HLA-B*15:02",
        "Gene": "HLA-B",
        "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
        "PMID": 38568509,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls. \"In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47). \"",
        "Sentence": "HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
        "Alleles": "*15:02",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": null,
        "Population Phenotypes or diseases": null,
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "38568509",
        "Variant Annotation ID_norm": "1452437420"
      },
      {
        "Variant Annotation ID": 1452438980,
        "Variant/Haplotypes": "HLA-B*13:01",
        "Gene": "HLA-B",
        "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
        "PMID": 38568509,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls.\"",
        "Sentence": "HLA-B *13:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
        "Alleles": "*13:01",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": null,
        "Population Phenotypes or diseases": null,
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "38568509",
        "Variant Annotation ID_norm": "1452438980"
      },
      {
        "Variant Annotation ID": 1452439000,
        "Variant/Haplotypes": "HLA-B*38:02",
        "Gene": "HLA-B",
        "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
        "PMID": 38568509,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls. \"In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47). \"",
        "Sentence": "HLA-B *38:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
        "Alleles": "*38:02",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": null,
        "Population Phenotypes or diseases": null,
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "38568509",
        "Variant Annotation ID_norm": "1452439000"
      },
      {
        "Variant Annotation ID": 1452439005,
        "Variant/Haplotypes": "HLA-B*15:02",
        "Gene": "HLA-B",
        "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
        "PMID": 38568509,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls. \"In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47). \"",
        "Sentence": "HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
        "Alleles": "*15:02",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": null,
        "Population Phenotypes or diseases": null,
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "38568509",
        "Variant Annotation ID_norm": "1452439005"
      }
    ],
    "var_fa_ann": []
  },
  "PMC12331468": {
    "pmid": "40786508",
    "title": "Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer",
    "study_parameters": [
      {
        "Study Parameters ID": 1454223606,
        "Variant Annotation ID": 1454223600,
        "Study Type": null,
        "Study Cases": 82.0,
        "Study Controls": null,
        "Characteristics": "neuropathy",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.05",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Latino",
        "Variant Annotation ID_norm": "1454223600"
      },
      {
        "Study Parameters ID": 1454223622,
        "Variant Annotation ID": 1454223640,
        "Study Type": null,
        "Study Cases": 82.0,
        "Study Controls": null,
        "Characteristics": "Hematological disorders",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.0005",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Latino",
        "Variant Annotation ID_norm": "1454223640"
      },
      {
        "Study Parameters ID": 1454223621,
        "Variant Annotation ID": 1454223640,
        "Study Type": null,
        "Study Cases": 82.0,
        "Study Controls": null,
        "Characteristics": "neuropathy",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.02",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Latino",
        "Variant Annotation ID_norm": "1454223640"
      },
      {
        "Study Parameters ID": 1454223623,
        "Variant Annotation ID": 1454223652,
        "Study Type": null,
        "Study Cases": 82.0,
        "Study Controls": null,
        "Characteristics": "Hematological disorders",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.005",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Latino",
        "Variant Annotation ID_norm": "1454223652"
      },
      {
        "Study Parameters ID": 1454223659,
        "Variant Annotation ID": 1454223625,
        "Study Type": null,
        "Study Cases": 82.0,
        "Study Controls": null,
        "Characteristics": "Skin and subcutaneous tissue disorders (recessive)",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.029",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Latino",
        "Variant Annotation ID_norm": "1454223625"
      },
      {
        "Study Parameters ID": 1454223681,
        "Variant Annotation ID": 1454223701,
        "Study Type": null,
        "Study Cases": 82.0,
        "Study Controls": null,
        "Characteristics": "Mucositis",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.036",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Latino",
        "Variant Annotation ID_norm": "1454223701"
      }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1454223600,
        "Variant/Haplotypes": "rs1801265",
        "Gene": "DPYD",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"Further analysis of ungrouped ADRs indicated a higher risk of neuropathy in patients carrying the C allele of the DPYD rs1801265 polymorphism ( Supplementary Table 3 , codominant model T/C genotype OR = 30.0, p-value = 0.0049, dominant model OR = 4.583, p-value = 0.05).\" Alleles complemented.",
        "Sentence": "Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.",
        "Alleles": "AG + GG",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Peripheral Nervous System Diseases",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": "AA",
        "Comparison Metabolizer types": null,
        "PMID_norm": "40786508",
        "Variant Annotation ID_norm": "1454223600"
      },
      {
        "Variant Annotation ID": 1454223640,
        "Variant/Haplotypes": "rs1695",
        "Gene": "GSTP1",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping ( Supplementary Table 3 , OR = 0.01, p-value = 0.008). However, we observed a higher risk of mucositis in patients carrying this polymorphism ( Supplementary Table 3 , OR = 2.27, p-value = 0.036).\"",
        "Sentence": "Genotype GG is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.",
        "Alleles": "GG",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": "AA + AG",
        "Comparison Metabolizer types": null,
        "PMID_norm": "40786508",
        "Variant Annotation ID_norm": "1454223640"
      },
      {
        "Variant Annotation ID": 1454223652,
        "Variant/Haplotypes": "rs11280056",
        "Gene": "TYMS",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"TYMS 3\u2019UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 \u2013 0.441, p-value =0.005).\"",
        "Sentence": "Genotypes TTA/TTA + TTA/TTAAAGTTA is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.",
        "Alleles": "TTA/TTA + TTA/TTAAAGTTA",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40786508",
        "Variant Annotation ID_norm": "1454223652"
      },
      {
        "Variant Annotation ID": 1454223625,
        "Variant/Haplotypes": "rs45445694",
        "Gene": "TYMS",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"3R genotype of TYMS 5\u2019UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).\"",
        "Sentence": "Genotype (GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3 is associated with increased likelihood of Hand-foot syndrome, Exanthema or Drug Toxicity when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.",
        "Alleles": "(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40786508",
        "Variant Annotation ID_norm": "1454223625"
      },
      {
        "Variant Annotation ID": 1454223701,
        "Variant/Haplotypes": "rs1695",
        "Gene": "GSTP1",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping ( Supplementary Table 3 , OR = 0.01, p-value = 0.008). However, we observed a higher risk of mucositis in patients carrying this polymorphism ( Supplementary Table 3 , OR = 2.27, p-value = 0.036).\"",
        "Sentence": "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.",
        "Alleles": "GG",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Mucositis",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": "AA + AG",
        "Comparison Metabolizer types": null,
        "PMID_norm": "40786508",
        "Variant Annotation ID_norm": "1454223701"
      }
    ],
    "var_fa_ann": []
  },
  "PMC12319246": {
    "pmid": "40761554",
    "title": "Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort",
    "study_parameters": [
      {
        "Study Parameters ID": 1454211336,
        "Variant Annotation ID": 1454211330,
        "Study Type": null,
        "Study Cases": 79.0,
        "Study Controls": null,
        "Characteristics": "acute rejection during 12-year follow-up, recipient",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.047",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1454211330"
      },
      {
        "Study Parameters ID": 1454211353,
        "Variant Annotation ID": 1454211347,
        "Study Type": null,
        "Study Cases": 79.0,
        "Study Controls": null,
        "Characteristics": "acute rejection during 12-year follow-up, donor",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.027",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1454211347"
      },
      {
        "Study Parameters ID": 1454211406,
        "Variant Annotation ID": 1454211400,
        "Study Type": null,
        "Study Cases": 79.0,
        "Study Controls": null,
        "Characteristics": "nephrotoxicity during 12-year follow-up, donor",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.024",
        "Ratio Stat Type": "Unknown",
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1454211400"
      },
      {
        "Study Parameters ID": 1454211266,
        "Variant Annotation ID": 1454211260,
        "Study Type": null,
        "Study Cases": 79.0,
        "Study Controls": null,
        "Characteristics": "exitus during 12-year follow-up",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.029",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1454211260"
      },
      {
        "Study Parameters ID": 1454211277,
        "Variant Annotation ID": 1454211271,
        "Study Type": null,
        "Study Cases": 79.0,
        "Study Controls": null,
        "Characteristics": "survival during 12-year follow-up",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.003",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1454211271"
      },
      {
        "Study Parameters ID": 1454211300,
        "Variant Annotation ID": 1454211280,
        "Study Type": null,
        "Study Cases": 79.0,
        "Study Controls": null,
        "Characteristics": "survival during 12-year follow-up",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.138",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1454211280"
      },
      {
        "Study Parameters ID": 1454211346,
        "Variant Annotation ID": 1454211340,
        "Study Type": null,
        "Study Cases": 79.0,
        "Study Controls": null,
        "Characteristics": "acute rejection during 12-year follow-up, recipient",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.024",
        "Ratio Stat Type": null,
        "Ratio Stat": null,
        "Confidence Interval Start": null,
        "Confidence Interval Stop": null,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1454211340"
      },
      {
        "Study Parameters ID": 1454211329,
        "Variant Annotation ID": 1454211323,
        "Study Type": null,
        "Study Cases": 79.0,
        "Study Controls": null,
        "Characteristics": "nephrotoxicity during 12-year follow-up",
        "Characteristics Type": "Study Cohort",
        "Frequency In Cases": null,
        "Allele Of Frequency In Cases": null,
        "Frequency In Controls": null,
        "Allele Of Frequency In Controls": null,
        "P Value": "= 0.026",
        "Ratio Stat Type": "OR",
        "Ratio Stat": 11.652,
        "Confidence Interval Start": 1.509,
        "Confidence Interval Stop": 89.957,
        "Biogeographical Groups": "Unknown",
        "Variant Annotation ID_norm": "1454211323"
      }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1454211330,
        "Variant/Haplotypes": "rs2740574",
        "Gene": "CYP3A4",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"Regarding acute rejection, statistical analysis showed that the CYP3A4 rs2740574 AA variant in the recipient could offer a protective effect (OR: 0.080; p-value: 0.047) compared to other variants at that location. \" Alleles complemented.",
        "Sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.",
        "Alleles": "TT",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Transplant rejection",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": "CC + CT",
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "1454211330"
      },
      {
        "Variant Annotation ID": 999001002,
        "Variant/Haplotypes": "rs6714486",
        "Gene": "UGT1A9",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "TA genotype associated with markedly increased risk of Acute rejection (OR 32.116; p=0.020); authors note skewed genotype distribution may inflate OR.",
        "Sentence": "Genotype TA is associated with increased likelihood of Acute rejection when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "TA",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Acute rejection",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "999001002"
      },
      {
        "Variant Annotation ID": 1454211347,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"The presence of the TT variant in SLCO1B1 rs4149056 in the recipient and the GT variant in CYP2B6 rs3745274 in the donor were also statistically associated with a reduced risk (OR: 0.16 and 0.2, respectively) of acute rejection.\"",
        "Sentence": "Genotype GT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "GT",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Transplant rejection",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "1454211347"
      },
      {
        "Variant Annotation ID": 1454211400,
        "Variant/Haplotypes": "rs2306283",
        "Gene": "SLCO1B1",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "From Table 3. AA and AG genotype of Recipient and AG genotype of donor were association with lower odds of nephrotoxicity",
        "Sentence": "Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "AA + AG",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Nephrotoxicity",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "1454211400"
      },
      {
        "Variant Annotation ID": 1454211260,
        "Variant/Haplotypes": "rs9282564",
        "Gene": "ABCB1",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"The AA variant in the rs9282564 SNP of the donor's ABCB1 gene was significantly associated (p-value: 0.029) with a reduced risk (OR: 0.116) of exitus during the follow-up period.\" \"The AG variant in ABCB1 gene rs9282564 of the donor was significantly associated (p-value: 0.042; log-rank) with reduced cumulative survival compared to the AA variant (Fig. 1A).\" Alleles complemented.",
        "Sentence": "Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.",
        "Alleles": "TT",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Efficacy:Death",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": "CC + CT",
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "1454211260"
      },
      {
        "Variant Annotation ID": 1454211271,
        "Variant/Haplotypes": "rs2273697",
        "Gene": "ABCC2",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"patients receiving a graft from a donor with the GA genotype in rs2273697 of ABCC2 were significantly associated (p-value: 0.021) with an increased risk (OR: 4.133) of exitus.\" \" It was observed that the genotype in the donor's ABCC2 rs2273697 could significantly (p-value: 0.003; log-rank) affect survival (Fig. 1B), with the GG variant providing a higher rate during the entire follow-up compared to AA and GA.\"",
        "Sentence": "Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.",
        "Alleles": "GG",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Overall survival",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": "AA + AG",
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "1454211271"
      },
      {
        "Variant Annotation ID": 1454211280,
        "Variant/Haplotypes": "rs776746",
        "Gene": "CYP3A5",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "\"Although the CYP3A5 rs776746 did not show a significant association with survival in logistic regression, the Kaplan-Meier curve was also represented (Fig. 1C) due to its special relevance and clinical evidence on the response to tacrolimus. No significant difference was observed by log-rank either, but it should not be discarded that the GG variant (\u22173/\u22173) could offer an advantage, especially at late post-transplantation stages.\" Alleles complemented. No *1*1 shown on kaplan meier, graph marked as recipient",
        "Sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.",
        "Alleles": "CC",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Overall survival",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": "CT",
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "1454211280"
      },
      {
        "Variant Annotation ID": 1454211340,
        "Variant/Haplotypes": "rs4149056",
        "Gene": "SLCO1B1",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"The presence of the TT variant in SLCO1B1 rs4149056 in the recipient and the GT variant in CYP2B6 rs3745274 in the donor were also statistically associated with a reduced risk (OR: 0.16 and 0.2, respectively) of acute rejection.\" \"Recipients with the TT variant in SLCO1B1 rs4149056 showed higher dose-adjusted tacrolimus concentrations, possibly mediating a greater immunosuppressive effect and protecting against rejection, consistent with our logistic regression results (OR: 0.157). \"",
        "Sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "TT",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Transplant rejection",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "1454211340"
      },
      {
        "Variant Annotation ID": 1454211323,
        "Variant/Haplotypes": "rs4244285",
        "Gene": "CYP2C19",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"An increased risk of nephrotoxicity was observed in patients receiving grafts carrying the AA variant in CYP2C19 rs4244285.\"",
        "Sentence": "Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "AA",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Nephrotoxicity",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "1454211323"
      },
      {
        "Variant Annotation ID": 999001006,
        "Variant/Haplotypes": "rs2066844",
        "Gene": "NOD2",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "CC genotype associated with reduced Nephrotoxicity risk (OR 0.015; p=0.035).",
        "Sentence": "Genotype CC is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "CC",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Nephrotoxicity",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "999001006"
      },
      {
        "Variant Annotation ID": 999001007,
        "Variant/Haplotypes": "rs1142345",
        "Gene": "TPMT",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "AA genotype associated with decreased likelihood of Re-transplantation (OR 0.048; p=0.020).",
        "Sentence": "Genotype AA is associated with decreased likelihood of Re-transplantation when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "AA",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Re-transplantation",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "999001007"
      },
      {
        "Variant Annotation ID": 999001008,
        "Variant/Haplotypes": "rs1799853",
        "Gene": "CYP2C9",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "CC genotype associated with decreased likelihood of Re-transplantation (OR 0.102; p=0.042).",
        "Sentence": "Genotype CC is associated with decreased likelihood of Re-transplantation when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "CC",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Re-transplantation",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "999001008"
      },
      {
        "Variant Annotation ID": 999001009,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "GT genotype associated with decreased Tumor incidence over 12-year follow-up (OR 0.099; p=0.048).",
        "Sentence": "Genotype GT is associated with decreased likelihood of Tumor incidence when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "GT",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Tumor incidence",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "999001009"
      },
      {
        "Variant Annotation ID": 999001010,
        "Variant/Haplotypes": "rs2273697",
        "Gene": "ABCC2",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "AA genotype associated with increased Tumor incidence (OR 13.091; p=0.043). GA genotype also associated with increased risk (OR 3.394; p=0.058).",
        "Sentence": "Genotype AA is associated with increased likelihood of Tumor incidence when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "AA",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Tumor incidence",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "999001010"
      },
      {
        "Variant Annotation ID": 999001013,
        "Variant/Haplotypes": "rs1045642",
        "Gene": "ABCB1",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "CC genotype associated with reduced Severe infections risk (OR 0.087; p=0.003).",
        "Sentence": "Genotype CC is associated with decreased likelihood of Severe infections when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "CC",
        "Specialty Population": null,
        "Metabolizer types": null,
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Severe infections",
        "Multiple phenotypes And/or": null,
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": null,
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Multiple phenotypes or diseases And/or": null,
        "Comparison Allele(s) or Genotype(s)": null,
        "Comparison Metabolizer types": null,
        "PMID_norm": "40761554",
        "Variant Annotation ID_norm": "999001013"
      }
    ],
    "var_fa_ann": []
  }
}